Estimation of Quality Adjusted Life Years (QALYs) for HIV Patients on Art in Kenya Using Proxy Utility Function
Asian Journal of Probability and Statistics,
Aims: This study seeks to estimate QALYs for HIV/AIDS patients on ART in Kenya to quantitatively evaluate the health impact of ART treatment on patients. QALYs values are important as they form a basis for evidence based decision making and policy formulation in the country with regards to HIV/ AIDS.
Study Design: The study involved secondary data obtained from a retrospective follow up study on hospital records of HIV/AIDS patients enrolled for ART from 2005 to 2017.
Place and Duration of Study: Jomo Kenyatta University of Agriculture and Technology, between January 2019-April 2022.
Methodology: The study involved a retrospective study of 3000 patients on ART in Kenya from the period of 2005-2017. All the patient records are identified using random patient id ensuring the privacy and anonymity of patients. The inclusion criteria is patients who had complete information on the covariates used in the model during follow up. The joint modelling of the longitudinal and survival data of each patient was applied and the results applied to proxy utility function to estimate the QALYs for patients on ART. To get the average QALYs gained by all patients, we aggregate the total QALYs from each patient. R. Software version 4.0.2 was used in the analysis.
Results: Sex, age, Marital Status and weight are significant predictors of survival of HIV Patients on ART in Kenya. Being on ART therapy resulted in a gain of 9.688313 QALYs for HIV/AIDS patients. The association parameter estimate is-0.0345 implying that increase in the values of CD4 count results in a decrease in the hazard of death for HIV patients on ART therapy.
Conclusion: The proxy utility function methodology is appropriate for the calculation of QALYs values for HIV patients on ART. It has the advantage of allowing utilities of each patient to vary and are calculated at every time point. Since ART results in the improvement in QALYs of patients, efforts should be directed towards ensuring patients who are enrolled for the therapy continue with it for sustained health and non health benefits.
How to Cite
Govender RD, Hashim MJ, Khan MA, Mustafa H, Khan G. Global epidemiology of HIV/AIDS: a resurgence in north America and Europe. J Epidemiol Glob Health. 2021;11(3):296-301.
Ejughemre U. Donor support and the impacts on health system strengthening in sub-Saharan Africa: assessing the evidence through a review of the literature. Am J Public Health Res. 2013;1(7):146-51.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093-103.
Neumann PJ, Cohen JT. Qalys in 2018 advantages and concerns. JAMA. 2018;319(24):2473-4.
Balestroni G, Bertolotti G. Euroqol-5d (eq-5d): an instrument for measuring quality of life. Monaldi Arch Chest Dis. 2012;78(3):155-9.
Horsman J, Furlong W, Feeny D, Torrance G. The health utilities index (hui®): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1(1):1-13.
Brazier JE, Dixon S, Ratcliffe J. The role of patient preferences in cost-effectiveness analysis: a conflict of values? Pharmacoeconomics. 2009;27(9):705-12.
Deo V, Grover G. A new approach to evaluate quality adjusted life years using proxy utility function-an application to HIV/AIDS data. J Commun Dis. 2019;51(3):1-9. (E-ISSN: 2581-351X & P-ISSN: 0019-5138).
Gueler A, Moser A, Calmy A, Günthard HF, Bernasconi E, Furrer H. et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS (Lond Engl). 2017;31(3):427-36.
Rizopoulos D. JM: an R package for the joint modelling of longitudinal and time-to-event data. J Stat Softw. 2010;35(9).
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271-92.
Devlin NJ, Lorgelly PK. Qalys as a measure of value in cancer. J Cancer Policy. 2017;11:19-25.
Garau M, Shah KK, Mason AR, Wang Q, Towse A, Drummond MF. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics. 2011;29(8):673-85.
Gold MR, Stevenson D, Fryback DG. Halys and qalys and Dalys, oh my: similarities and differences in summary measures of population health. Annu Rev Public Health. 2002;23(1):115-34.
Grover G, Gadpayle AK, Swain PK et al. A multistate markov model based on CD4 cell count for HIV/AIDS patients on antiretroviral therapy (ART). Int J Stat Med Res. 2013;2:144-51.
Johannesson M, Pliskin JS, Weinstein MC. A note on QALYs, time tradeoff, and discounting. Med Decis Making. 1994;14(2):188-93.
Markowitz HM, Reid DW, Tew BV. The Value of a Blank Check. J Portfol Manag. 1994;20(4):82-91.
Merton RC, Samuelson PA. Fallacy of the log-normal approximation to optimal portfolio decision-making over many periods. J Financ Econ. 1974;1(1):67-94.
Rudmik L, Drummond M. Health economic evaluation: important principles and methodology. Laryngoscope. 2013;123(6):1341-7.
Shoko C, Chikobvu D. Time-homogeneous Markov process for HIV/AIDS progression under a combination treatment therapy: cohort study, South Africa. Theor Biol Med Model. 2018;15(1):3.
Tseng YK, Hsieh F, Wang JL. Joint modelling of accelerated failure time and longitudinal data. Biometrika. 2005;92(3):587-603.
Tsiatis AA, Davidian M. Joint modeling of longitudinal and time-to-event data: an overview. Stat Sin. 2004;14:809-34.
Wu B, Li T, Cai J, Xu Y, Zhao G. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer. 2014;14:984.
Abstract View: 60 times
PDF Download: 23 times